-
The Women's Health Initiative (WHI) investigators conducted a secondary analysis of the two canceled clinical trial arms.
-
The Estrogen and ThromboEmbolism Risk (ESTHER) study is a case-control study performed with cases from 8 French hospitals and controls from the general population.
-
IBS-Drug Treatment Pulled, CV Side Effects; Drug Combo Better for Migraine Treatment; Pergolide Off the Market, Heart Disease Risk; Hormone Treatment, Does Timing Matter?; FDA Actions
-
-
Cole and colleagues from i3 Drug Safety reported that the use of the transdermal contraceptive system was associated with a 2.4-fold increase in the risk of venous thromboembolism compared with users of a 35 µg ethinyl estradiol and norgestimate oral contraceptive.1 i3 Drug Safety is a unit of Ingenix, a medical information company owned by United Health Group.
-
These New Jersey authors hypothesized that attire and patient satisfaction would be unrelated. For 3 months, full-time faculty, both generalists and subspecialists, were randomly assigned to different attire, ie, business attire, casual clothing, or scrubs.
-
First Antihypertensive Drug Approved in Last 10 Years: Aliskiren; Alternate Treatment for Osteoporosis; Roche's Oseltamivir: Scrutiny, Bird Flu, and New Drug Applications; FDA Actions
-
In this retrospective study, the authors gleaned hospital records to identify cases of adnexal torsion at their hospital in Israel between 2002 and 2006. Sixty-two cases were found appropriate for the study.
-
It has not been clear as to whether a cervical conization truly predisposes a patient to preterm birth (PTB). The authors of this enlightening paper set out to see if the interval between the procedure and subsequent conception had any effect on the incidence of PTB.
-
Legro and colleagues, reporting for the Cooperative Multicenter Reproductive Medicine Network, presented the results of a multicenter, randomized trial indicating that clomiphene is superior to metformin in achieving live births in women with the polycystic ovary (PCO) syndrome.
